Why the study?
Observational studies have shown benefits of DOACs over warfarin against ischemic stroke, motivating an investigation of ischemic stroke incidence and bleeding risk with DOAC therapy in NVAF.
Do direct-acting oral anticoagulants improve clinical outcomes (MACCEs and bleeding) compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Population
4,773 elderly patients with NVAF prescribed anticoagulants in Korea
Comparison
DOACs (rivaroxaban, dabigatran, or warfarin-to-rivaroxaban switchers) vs warfarin or head-to-head
Design
Retrospective propensity score-matched cohort study
Authors
Loading...
May warrant preferring dabigatran over rivaroxaban for bleeding risk in elderly NVAF; leaves open need for randomized confirmation.
Do direct-acting oral anticoagulants improve clinical outcomes (MACCEs and bleeding) compared to warfarin in elderly patients with non-valvular atrial fibrillation?
In elderly Korean patients with NVAF, DOACs and warfarin showed similar efficacy and safety, though rivaroxaban was associated with a higher bleeding risk compared to dabigatran.
Hong et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: